Table 1

Full-text case series, number of patients, anticoagulant and indication for anticoagulation

Case seriesNAnticoagulant, n (%)Indication, n (%)Bleed location, n (%)
AEdRAFDVT/PEOtherICHGIOther
Barra et al20113 (27)0 (0)8 (73)8 (73)3 (27)NR11 (100)0 (0)0 (0)
Korobey et al255940 (68)0 (0)19 (32)49 (83)16 (27)NR59 (100)0 (0)0 (0)
Reynolds et al273114 (45)0 (0)17 (55)22 (71)6 (19)3 (10)17 (55)7 (23)7 (23)
Arachchillage et al198040 (50)0 (0)40 (50)68 (85)13 (16)0 (0)46 (58)24 (30)10 (13)
Dybdahl et al213517 (49)0 (0)18 (51)31 (89)5 (14)0 (0)35 (100)0 (0)0 (0)
Frontera et al224631 (67)0 (0)15 (33)44 (96)3 (7)NR35 (76) *11 (24)0 (0)
Smith et al313117 (55)0 (0)14 (45)28 (90)3 (10)NR18 (58)1 (3)12 (39)
Allison et al18336 (18.0 (0)27 (82)24 (73)6 (18)3 (9)30 (91)1 (3)2 (6)
Harrison et al2414NRNRNR12 (86)3 (21)2 (14)14 (100)0 (0)0 (0)
Schenk et al28130 (0)0 (0)13 (100)NRNRNR10 (77)1 (8)2 (15)
Schulman et al296629 (44)0 (0)37 (56)56 (85)10 (15)1 (2)36 (55)16 (24)15 (21)
Sheikh-Taha30 20182913 (45)0 (0)16 (55)23 (79)5 (17)1 (3)21 (72)4 (14)4 (14)
Majeed et al268439 (46)0 (0)45 (54)67 (80)21 (25)21 (25)59 (70)13 (16)12 (14)
Grandhi et al23182 (11)0 (0)16 (89)16 (89)1 (6)3 (17)18 (100)0 (0)0 (0)
  • *Study pooled intracranial haemorrhage and intraspinal bleed.

  • A, apixaban; AF, atrial fibrillation; DVT, deep vein thromboembolism; Ed, edoxaban; GI, gastrointestinal; ICH, intracranial haemorrhage; NR, not recorded; PE, pulmonary embolism; R, rivaroxaban.